Literature DB >> 15696088

A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy.

Fatimah Kussebi1, Fariba Karamloo, Claudio Rhyner, Peter Schmid-Grendelmeier, Maria Salagianni, Christian Mannhart, Mübeccel Akdis, Lyudmilla Soldatova, Zora Markovic-Housley, Barbara R Von Beust, Thomas Kündig, David M Kemeny, Kurt Blaser, Reto Crameri, Cezmi A Akdis.   

Abstract

BACKGROUND: Specific immunotherapy is a common treatment of allergic diseases and could potentially be applied to other immunologic disorders. Despite its use in clinical practice, more defined and safer allergy vaccine preparations are required. Differences between epitopes of IgE that recognize the 3-dimensional structure of allergens and T cells that recognize linear amino acid sequences provide a suitable tool for novel vaccine development for specific immunotherapy.
OBJECTIVE: The aim of the study was to delete B-cell epitopes and prevent IgE crosslinking, but to preserve T-cell epitopes by fusion of 2 major allergens of bee venom because of a change in the conformation.
METHODS: By genetic engineering, we produced a fusion protein composed of the 2 major bee venom allergens: phospholipase A 2 (Api m 1) and hyaluronidase (Api m 2).
RESULTS: The Api m [1/2] fusion protein induced T-cell proliferation and both T H 1-type and T H 2-type cytokine responses. In contrast, IgE reactivity was abolished, and profoundly reduced basophil degranulation and type 1 skin test reactivity was observed. Pretreatment of mice with Api m [1/2] fusion protein significantly suppressed the development of specific IgE as well as other antibody isotypes after immunization with the native allergen.
CONCLUSION: The novel fusion protein of 2 major allergens bypasses IgE binding and mast cell/basophil IgE FcepsilonRI crosslinking and protects from IgE development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15696088     DOI: 10.1016/j.jaci.2004.11.041

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

Review 1.  Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences.

Authors:  L Li; V Boussiotis
Journal:  Chem Immunol Allergy       Date:  2008

Review 2.  T-cell subsets in the pathogenesis of human asthma.

Authors:  Flurina Meiler; Maya Zimmermann; Kurt Blaser; Cezmi A Akdis; Mübeccel Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

3.  A DNA vaccine encoding a chimeric allergen derived from major group 1 allergens of dust mite can be used for specific immunotherapy.

Authors:  Tong Sun; Kang Yin; Lu-Yi Wu; Wen-Jie Jin; Yang Li; Bin Sheng; Yu-Xin Jiang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 4.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 5.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 6.  Modified Allergens for Immunotherapy.

Authors:  Pattraporn Satitsuksanoa; Anna Głobińska; Kirstin Jansen; Willem van de Veen; Mübeccel Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-16       Impact factor: 4.806

Review 7.  Therapeutic manipulation of immune tolerance in allergic disease.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

Review 8.  Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells.

Authors:  Alison Taylor; Johan Verhagen; Kurt Blaser; Mübeccel Akdis; Cezmi A Akdis
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

Review 9.  Therapies for allergic inflammation: refining strategies to induce tolerance.

Authors:  Cezmi A Akdis
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

10.  A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.

Authors:  Julia M Martínez Gómez; Stefan Fischer; Noèmi Csaba; Thomas M Kündig; Hans P Merkle; Bruno Gander; Pål Johansen
Journal:  Pharm Res       Date:  2007-05-31       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.